Inhibrx Biosciences
INBX | NASDAQ
$77.66
-$5.64 (-6.77%)
At close: Nov 16, 2026, 4:00 PM ET
$77.55
-$0.11 (-0.14%)
After-hours:
Nov 16, 2026, 7:32 PM ET
Inhibrx Biosciences Company Profile
Company profile explainedCompany Profile
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer |
| Bonne Adams | Vice President of Operations |
| Carlos Bais | EVice President & Chief Scientific Officer |
| David Matly | President |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer |
| Kate Burke | Vice President of Accounting |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 4 | Filing |
| Sep 18, 2026 | 4/A | [Amend] Filing |
| Sep 18, 2026 | 4/A | [Amend] Filing |
| Sep 18, 2026 | 4/A | [Amend] Filing |
| Sep 18, 2026 | 4/A | [Amend] Filing |
| Sep 17, 2026 | 4 | Filing |
Inhibrx Biosciences
| Country | United States |
| IPO Date | May 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Mark Lappe |
Contact Details
11025 North Torrey Pines Road La Jolla,
California 92037 United States
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002007919 |
| CUSIP Number | 45720N103 |
| ISIN Number | US45720N1037 |
| SIC Code | 2836 |
Recent News
- 3 days ago / prnewswire.comInhibrx Reports Third Quarter 2026 Financial Results
- 1 month ago / prnewswire.comInhibrx Announces Participation in Upcoming Scientific Conferences
- 2 months ago / marketbeat.comInhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- 2 months ago / fool.comInhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
- 2 months ago / seekingalpha.comInhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
- 2 months ago / seekingalpha.comInhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
- 2 months ago / benzinga.comInhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
- 2 months ago / reuters.comInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
- 2 months ago / prnewswire.comInhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
- 3 months ago / prnewswire.comInhibrx Reports Second Quarter 2026 Financial Results
Add to Watchlist
Select watchlists to add or remove INBX